The dermis is an ideal tissue for delivering large molecules such as peptides and mAbs, as this layer contains a vast network of blood capillaries and lymphatic vessels, which traffic larger molecules to systemic circulation.
Emerging evidence suggests that intradermal delivery of biologics offers significant therapeutic benefits across various drug classes and indications:
Alternative ROAs are important considerations for product life cycle management strategies and for providing more patient-centric administration options compared to IV infusions.
Intradermal delivery offers several key advantages for monoclonal antibodies (mAbs), primarily by improving lymphatic access. This leads to:
mAbs are increasingly being used to treat dermatological conditions, and intradermal delivery can offer:
Thanks to our innovative intradermal self-injector, our technology is perfectly suited for chronic dermatological applications that require regular at-home administration. By seamlessly integrating our advanced core technology into this self-injection device, we enable precise intradermal self-administration easily and conveniently.
The intradermal route is the ideal choice for treating skin conditions and dermatological applications. By delivering treatment directly to the affected area, intradermal administration targets the problem site more effectively, potentially reducing systemic side effects. This makes it particularly well-suited for dermatological conditions such as skin cancer or autoimmune skin disorders, where localized treatment is crucial for optimal outcomes.
